MARKET

GRAL

GRAL

Grail Inc
NASDAQ
50.78
+1.63
+3.32%
After Hours: 50.38 -0.4 -0.79% 19:50 04/08 EDT
OPEN
53.00
PREV CLOSE
49.15
HIGH
53.90
LOW
48.48
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
118.84
52 WEEK LOW
20.44
MARKET CAP
2.08B
P/E (TTM)
-4.5705
1D
5D
1M
3M
1Y
5Y
1D
GRAIL Epic Integration Puts Galleri Uptake And Valuation In Focus
Simply Wall St · 7h ago
Grail, Epic Plan Galleri Test Integration For 450 Health Systems
Benzinga · 18h ago
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
Seeking Alpha · 18h ago
Grail announces collaboration with Epic to bring Galleri test to EHR platforms
TipRanks · 1d ago
GRAIL Collaborates With Epic To Bring Galleri Multi-Cancer Early Detection Test Into Electronic Health Record Platforms, Supporting Broader Adoption Across Health Systems In US
Benzinga · 1d ago
Grail partners with Epic to integrate Galleri cancer test into EHR platform
Reuters · 1d ago
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
PR Newswire · 1d ago
Evaluating GRAIL (GRAL) After Superpower Partnership Expands Access To Galleri Test
Simply Wall St · 1d ago
More
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Webull offers Grail Inc stock information, including NASDAQ: GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.